(Reuters)-The American Pharmaceutical Company raised its profit expectations throughout the year on Tuesday, after it reported better results than expected for the second quarter, which was strengthened by the strong demand for heart disease, Fendell, and the bloodshed, Elis.
The pharmaceutical maker now expects to earn between $ 2.90 to $ 3.10 a share on the basis of an amendment in 2025, compared to its previous expectations from $ 2.80 to $ 3.00 per share.
The shares of the pharmaceutical maker increased by 2.4 % in the market hours.
Pfizer said the new expectations include an effect of 20 cents per share in relation to the last license deal with 3SBIO in China to treat experimental cancer.
Pfizer results come at a time when the pharmaceutical industry is under pressure from President Donald Trump’s management to a decrease in drug prices and is preparing for 15 % definitions on imports from the European Union.
The pharmaceutical maker said it has enough manufacturing capacity across its ten sites in the United States to alleviate any effect of customs tariffs and is open to convert some production into these existing facilities.
Investors are also closely monitoring the potential disturbances of the Other Companies Valley Portfolio of changes under RFK JR. , It is a known form. Vaccine represents about 20 % of Fayzer’s revenues.
On an average basis, PFIZER got 78 cents per share in the second quarter, compared to the expectations of the 58 cents analysts per share, according to LSEG data.
(Participated in Hanafi Satiga reports in Bangaluru and Michael Irman in New York; Liberation by Anil Delva)
https://media.zenfs.com/en/reuters-finance.com/b07c242360c0a88fcf19cbb3da7cb306
Source link